The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Trust Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by the Wellcome Trust.